Serum pentraxin 3 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Trojak, Aleksandra; Waluś-Miarka, Małgorzata; Kapusta, Maria; Miarka, Przemysław; Kawalec, Ewa; Idzior−Waluś, Barbara; Małecki, Maciej

doi:10.20452/pamw.14913

Cited by 8 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A further study described a positive association of PTX3 mRNA expression in white blood cells with low-density lipoprotein [13,14]. Accordingly, serum PTX3 was positively correlated with LDL-cholesterol in a cohort of type 2 diabetes patients [15]. Notably, type 2 diabetes patients with NAFLD had serum PTX3 levels as high as patients with normal liver function illustrating an association of serum PTX3 with dyslipidemia rather than NAFLD [13,15].…”

Section: Introductionmentioning

confidence: 91%

“…Accordingly, serum PTX3 was positively correlated with LDL-cholesterol in a cohort of type 2 diabetes patients [15]. Notably, type 2 diabetes patients with NAFLD had serum PTX3 levels as high as patients with normal liver function illustrating an association of serum PTX3 with dyslipidemia rather than NAFLD [13,15]. Anyhow, a separate study described an association of plasma PTX3 with the stages of liver fibrosis in patients with NAFLD [16].…”

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

et al. 2020

View full text Add to dashboard Cite

The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.

show abstract

Section: Introductionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 94%

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, in our cohort of DM2 patients, we found significant associations between PTX3 and atherogenic lipids and Apo B100 and Apo C3 levels in patients with non-alcoholic fatty liver disease, further supporting PTX3 as marker of increased vascular risk. 30…”

Section: Discussionmentioning

confidence: 99%

Correlates of pentraxin 3 serum concentration in men and women with type 2 diabetes

Waluś-Miarka

Trojak

Miarka³

et al. 2019

Innate Immun

Self Cite

View full text Add to dashboard Cite

Elevated levels of plasma pentraxin 3 (PTX3), a marker of inflammation, are associated with the risk of developing cardiovascular diseases in the general population, as well as in patients with type 2 diabetes (DM2). In this study, we aimed to determine factors associated with PTX3 serum concentrations in men and women with DM2. The study included 116 consecutive patients (67 men and 49 women) with DM2 from an outpatient diabetic clinic. Men were characterised by lower age and higher uric acid, creatinine and bilirubin concentrations and waist/hip ratio than women. In women, low-density lipoprotein cholesterol (LDL-C) levels were higher than in men. In men, median (interquartile range) values of PTX3 concentration were 4.02 (1.99), and in women they were 4.53 (3.31) ng/ml (NS). In men, PTX3 concentrations correlated with total cholesterol (TC), triglycerides, apolipoprotein (Apo) C3, Apo B48, Glc and creatinine levels. In women, PTX3 correlated significantly with TC and LDL-C and Apo B100. Partial regression analysis revealed that after adjusting for age, PTX3 concentrations in men were significantly associated with TC, LDL-C, triglycerides, creatinine, Apo C3 and Apo B48, while in women they were associated with TC, LDL-C and Apo B100. The results could be of importance in sex-specific prevention of vascular complications in DM2 patients.

show abstract

“…The surge in pro-inflammatory cytokines such as interleukins (IL), tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1 and plasminogen activator inhibitor (PAI)-1 along with the decline in anti-inflammatory cytokines (IL-7, IL-10, and adiponectin) enhances the effect of lingering inflammation [8,9,12]. The evidence of chronic injury and resultant inflammation is supported by the presence of acute-phase reactant pentraxin and high sensitivity c-reactive protein (hs-CRP) emerging as an important marker of liver fibrosis and steatohepatitis further confirming the responsibility for continued irritation [14].…”

Section: Introductionmentioning

confidence: 90%

“…It has a dual role in the inflammatory pathway. It counteracts IL-1, TNFα, infectious agents induced inflammatory route but, on the other hand, it has strong connections with apolipoprotein (Apo)-C3, Apo-B100, which serves as a marker for atherogenic hepatic lipoproteins like very-low-density lipoprotein (VLDL) and sdLDL small density LDL (sdLDL) which are involved in direct systemic inflammation [14].…”

Section: Pro-inflammatory and Anti-inflammatory Cytokinesmentioning

confidence: 99%

Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review

Yaqub¹,

Ananias²,

Shah³

et al. 2021

Cureus

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic manifestation of metabolic syndromes, and its roots are strongly associated with obesity and insulin resistance. The excess fat induces inflammatory pathways by tissue irritation and progresses to non-alcoholic steatohepatitis (NASH), fibrosis, and has emerged as the most frequent cause of hepatocellular cancer (HCC). This systematic review was structured per the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. The evidence was obtained from 13 research articles published in PubMed, Google Scholar, and Science Direct databases, including cross-sectional, case-control, prospective cohort studies, meta-analysis, and systematic reviews. The inclusion/exclusion criteria of free articles, published in English involving humans of mid-age in the last five years were applied. This review highlights findings in 7781 individuals, including non-NAFLD, NAFLD, and NASH positive individuals based on anthropometric measurement, blood samples, FibroScan, flow cytometry, and liver biopsy. The results underscored that the onset of inflammation set on the background of NAFLD starts NASH; the understanding and control of inflammation will help us design definitive biomarkers and treatment modalities. The complex pathogenesis and comparatively slow advancement but high morbidity have led investigators to understand the nuts and bolts for early management and prevention. Lipotoxicity and dysbiosis stimulate the immune system to generate cytokines and chemokines and decline in adipokines. The role of proteinase3 (PR3) and antitrypsin (ATT) ratio and biliverdin reductase (BVR) compel the exploration for non-invasive tests for definitive therapy.

show abstract

Serum pentraxin 3 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Cited by 8 publications

References 23 publications

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Correlates of pentraxin 3 serum concentration in men and women with type 2 diabetes

Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review

Contact Info

Product

Resources

About